Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1806 results about "Pneumonitis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mainly refers to inflammation of lung tissue due to non-infectious causes.
Multivalent pneumococcal polysaccharide-protein conjugate composition
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
Owner:WYETH LLC
Human antipneumococcal antibodies from non-human animals
Owner:ABQENIX INC
Streptococcus pneumoniae SP042 polynucleotides
The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneumoniae. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of Streptococcus pneumoniae. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting Streptococcus nucleic acids, polypeptides and antibodies in a biological sample.
Owner:HUMAN GENOME SCI INC
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
InactiveUS7098023B1Easy to adaptSugar derivativesBacteriaStreptococcus pneumoniaeNucleic acid sequencing
The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
Owner:SANOFI PASTEUR LTD
Intra-bronchial obstruction device that provides a medicant intra-bronchially to the patient
An intra-bronchial device provides a medicant intra-bronchially. The medicant may be used for controlling biological interaction of an intra-bronchial obstruction device with the patient, to treat a disease or condition of the lungs such as pneumonia or lung cancer, or to treat a systemic disease or condition. The medicant is provided by associating a medicant with the intra-bronchial device, either before, at the time of placement, or after placement. The medicant may overlie at least a portion of the intra-bronchial device, be absorbed into at least a portion of the intra-bronchial device, or be carried in a chamber. The intra-bronchial device may further include an absorptive member, and the medicant is absorbed by the absorptive member.
Owner:GYRUS ACMI INC (D B A OLYMPUS SURGICAL TECH AMERICA)
Methods, devices and formulations for targeted endobronchial therapy
ActiveUS20050235987A1Mortality rate is decreasedReduce morbidityAntibacterial agentsTracheal tubesTracheobronchitisRegimen
The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
ActiveUS20080261887A1Reduce severityReduce morbidityPeptide/protein ingredientsAntiviralsDiseaseClinical manifestation
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
InactiveUS7074914B1Easy to adaptAntibacterial agentsOrganic active ingredientsStreptococcus pneumoniaeNucleic acid sequencing
Owner:SANOFI PASTEUR LTD
Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same
Owner:LEGEND WIN FINANCE
Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
The present invention relates to certain novel dinucleotides and formulations thereof which are highly selective agonists of the P2Y2 and / or P2Y4 purinergic receptor. They are useful in the treatment of chronic obstructive pulmonary diseases such as chronic bronchitis, PCD, cystic fibrosis, as well as prevention of pneumonia due to immobility. Furthermore, because of their general ability to clear retained mucus secretions and stimulate ciliary beat frequency, the compounds of the present invention are also useful in the treatment of sinusitis, otitis media and nasolacrimal duct obstruction. They are also useful for treatment of dry eye disease and retinal detachment as well as facilitating sputum induction and expectoration.
Owner:MERCK SHARP & DOHME CORP
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
InactiveUS7081530B1Easy to adaptBacteriaSugar derivativesStreptococcus pneumoniaeNucleic acid sequencing
The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
Owner:SANOFI PASTEUR LTD
Methods, devices and formulations for targeted endobronchial therapy
ActiveUS20050211245A1Mortality rate is decreasedReduce morbidityAntibacterial agentsTracheal tubesTracheobronchitisRegimen
The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Human mycoplasma pneumoniae gold-marked silver-stained immunochromatographic assay kit and preparation method and application thereof
The invention provides a human mycoplasma pneumoniae gold-marked silver-stained immunochromatographic assay kit and a preparation method and application thereof. The assay kit comprises a detection card and a silver-stained sensitivity-enhanced pad, wherein the detection card is composed of a bottom plate, a sample pad, an absorbent pad, a conjugate pad and a detection layer; the conjugate pad is coated with a colloidal gold-marked polyclonal antibody mixture of colloidal gold marked rabbit anti-human mycoplasma pneumoniae P1 protein and P30 protein; the detection layer is composed of a solid phase nitrocellulose membrane with a detection line and a quality control line; the detection layer is bonded on the bottom plate, the conjugate pad and the absorbent pad are partially overlapped with the detection layer respectively and are bonded with the detection layer and the bottom plate respectively; the sample pad and the conjugate pad are partially overlapped to be bonded with the conjugate pad and the bottom plate respectively; and the silver-stained sensitivity-enhanced pad consists of a AgNO3 pad and a restoring pad. The human mycoplasma pneumoniae gold-marked silver-stained immunochromatographic assay kit can effectively improve the detection sensitivity of the human mycoplasma pneumoniae, has the strong specificity and has the high application value in the aspects of clinical diagnosis of human mycoplasma pneumoniae, etiology identification, epidemiological investigation and the like.
Owner:HUBEI UNIV OF TECH +1
Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
Owner:KANEKA CORP
Methods, devices and formulations for targeted endobronchial therapy
ActiveUS20050211253A1Mortality rate is decreasedReduce morbidityAntibacterial agentsTracheal tubesTracheobronchitisTreatment effect
The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airnvays distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Migration learning lung lesion tissue detection system based on MaskScoring R-CNN network
ActiveCN110599448AMeet high precisionStrong generalizationImage enhancementImage analysisNetwork modelLung cancer
A migration learning lung lesion tissue detection system based on an MaskScoring R-CNN network comprises a storage module for storing four lung diseases including lung cancer, pneumonia, pulmonary tuberculosis and emphysema and further comprises a diagnosis module, and the diagnosis module is in communication connection with the storage module and comprises the following steps of 1) preprocessinga medical image; 2) constructing the MaskScoring R-CNN network model, wherein the step 2) specially comprises 1, constructing a shared convolutional neural network backbone (for feature extraction); 2, carrying out transfer learning on a shared convolutional neural network; 3, constructing an FPN network; 4, constructing an RPN network; 5, constructing an ROIAlign layer; 6, adding the MaskIoU head; and 3) identifying the lung medical image lesion tissue, inputting a to-be-detected lung CT image into the constructed MaskScoring R-CNN network, outputting and obtaining an identified image by thenetwork, framing out and masking the identified lesion tissues, and marking the lesion categories. According to the method, the requirement for high precision of medical image segmentation is met, andthe network can have the good generalization.
Owner:ZHEJIANG UNIV OF TECH
Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
InactiveUS20090317423A1Reduce incidenceEffective immunityViral antigen ingredientsAntiinfectivesDiseaseActive component
Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Methods and compositions for disease treatment using inhalation
InactiveUS20120077786A1Increasing subject 's convenienceGood treatment complianceBiocideOrganic active ingredientsPulmonary edemaLung cancer
Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.
Owner:MICRODOSE THERAPEUTX INC
Airway implant devices and methods of use
InactiveUS20060037617A1Improved ability to breatheImproved to to talkRespiratorsBreathing masksPhysical medicine and rehabilitationEngineering
The invention is drawn to airway implant devices that can alleviate and remediate the effects of dysphagia and aspiration that occur under a wide range of clinical conditions, such as Parkinson's disorder, Alzheimer's disease, or stroke. The devices can further be used to reduce the risk of onset of aspiration pneumonia in these and many other clinical conditions.
Owner:WALKE AMRISH JAYPRAKASH +5
Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and / or to rescue negative strand RNA recombinant viruses that express, package, and / or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.
Owner:VIRONOVATIVE
immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
InactiveUS6042838ALittle or no tropism for the GALTGood mucosal immunogenAntibacterial agentsBacterial antigen ingredientsCoccidiaPneumococcal surface protein A
Mucosal administration, particularly intranasally, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with cholera toxin B subunit, provides protection in animals against pneumococcal colonization and systemic infection. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
Owner:UNIVERSITY OF ALABAMA
Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
ActiveUS8324218B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderDiseaseSinusitis
The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.
Owner:PARION SCI DURHAM NC
Sulfonated derivative of andrographolide and combination of medication
ActiveCN1687049AClear structureGood antibacterialAntibacterial agentsPowder deliveryDiseaseTonsillitis
The present invention discloses II kinds of andrographolide sulfonated derivatives with the actions of resisting bacteria, relieving inflammation and reducing fever and medicine composition containing them. They can be used for preparing freeze-dried powder, injection or oral preparation, and can be used for curing the diseases of pneumonia, bronchitis, tonsillitis and bacillary dysentery, etc.
Owner:JIANGZI QINGFENG PHARMACEUTICALS INC
Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
ActiveUS20080182797A1Avoid tissue damageLevel of protectionNervous disorderTetrapeptide ingredientsPregnancyAllograft rejection
This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia / reperfusion (I / R) injury of various tissues (e.g., I / R injury of heart muscle associated with heart attack or cardiac surgery, I / R injury of brain tissue associated with stroke, I / R injury of liver tissue, skeletal muscles, etc.), septic shock, anaphylactic shock, neurodegenerative diseases (e.g., Alzheimer's and Parkinson's diseases), neuronal injury, atherosclerosis, diabetes, multiple sclerosis, autoimmune uveitis, pulmonary fibrosis, oobliterative bronchiolitis, bronchopulmonary dysplasia (BPD), amyotrophic lateral sclerosis (ALS), sepsis, inflammatory bowel disease, arthritis, allograft rejection, autoimmune myocarditis, myocardial inflammation, pulmonary granulomatous inflammation, influenza- or HSV-induced pneumonia, chronic cerebral vasospasm, allergic encephalomyelitis, central nervous system (CNS) inflammation, Heliobacterium pylori gastritis, necrotizing entrerocolitis, celliac disease, peritonitis, early prosthesis failure, inclusion body myositis, preeclamptic pregnancies, skin lesions with anaphylactoid purpura, nephrosclerosis, ileitis, leishmaniasis, cancer, and related disorders.
Owner:NEW YORK UNIVERSITY
Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient
InactiveUS7494987B2Potent antitussive actionImprove securityAntibacterial agentsBiocideDiseaseCarboxyl radical
An agent for preventing / treating respiratory diseases contains, as an active ingredient, a compound represented by following Formula (I):wherein A is a group represented by L-W [wherein L is a bond or CH2; and W is O, SOn (wherein n is 0 to 2), or —NR7— (wherein R7 is hydrogen or lower alkyl)]; each of G1 and G2 is (CH2)r (wherein r is 0 to 2), provided that when n is 1, G1 and G2 may be bridged by lower alkylene; Y is a lower alkylene or (substituted) benzylidene; Z is a bond or O, provided that when Z is a bond, Y may form a 5- or 6-membered ring with carbon on the benzene ring; R1 is, for example, NO2, a lower alkoxycarbonyl, (substituted) carbamoyl, (protected) hydroxyl group, (protected) carboxyl, or (protected) N-hydroxycarbamoyl; each of R2 and R3 is hydrogen, halogen, (halogenated) lower alkyl, (halogenated) lower alkoxy or NO2; each of R4 and R5 is, for example, hydrogen, halogen, (halogenated) lower alkyl, (halogenated) lower alkoxy, CN, or lower alkylsulfonyl; and R6 is hydrogen or lower alkyl, a salt thereof or a solvate of them. It has excellent antitussive activity when used as an agent for preventing / treating respiratory diseases such as lung cancer, common cold syndrome, pulmonary tuberculosis, pneumonia, acute bronchitis or chronic bronchitis.
Owner:MOCHIDA PHARM CO LTD
Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
Owner:KANEKA CORP
Mucosal administration of pneumococcal antigens
InactiveUS6027734ALittle or no tropism for the GALTGood mucosal immunogenAntibacterial agentsBiocideDiseasePneumococcal antigen
Mucosal administration, particularly intranasally, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with cholera toxin B subunit, provides protection in animals against pneumococcal colonization and systemic infection. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
Owner:UAB RES FOUND
Streptococcal heat shock proteins of the Hsp60 family
Methods and compositions comprising isolated nucleic acid molecules specific to Streptococcus pneumoniae and Streptococcus pyogenes, as well as vector constructs and isolated polypeptides specific to Streptococcus pneumoniae and Streptococcus pyogenes are provided. Such compositions and methods are useful for the diagnosis of Streptococcal infection and for generating an immune response to Streptococcal bacteria.
Owner:NVENTA BIOPHARMACEUTICALS CORP
Vaccine
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
InactiveUS20060287267A1Improves various propertyImprove the immunityBiocideSugar derivativesLipid formationDisease
This invention relates to compounds, compositions, and methods useful for modulating sespiratory syncytial virus (RSV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RSV gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of RSV genes, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such such small nucleic acid molecules cocktails thereof. The application also relates to methods of treating diseases and conditions associated with RSV gene expression, such as RSV infection, respiratory failure, bronchiolitis and pneumonia, as well as providing dosing regimens and treatment protocols.
Owner:SIRNA THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com